Skip to main content

EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE

Objective

CLINICAL NEED
Every year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases. Currently there are no tools available that allow for:
a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or;
b) Stratification of patients into optimal personalised therapy regimes in ovarian/breast cancer.

EpiFemCare ADVANCES
Progress in personalised cancer medicine will only be possible with the development of bioassays involving the analysis of easy accessible biomaterials that contain stable target molecules reflective of disease. We will establish and clinically validate a series of blood tests based upon DNA methylation technology that will facilitate both early detection and prediction of therapeutic outcome in breast and ovarian cancer.

CONSORTIUM
Our pan-European academic-industrial consortium demonstrates diverse clinical, scientific & industrial expertise. We have access to the latest state of the art technologies and, integrally, the best available cohort and clinical trial sample sets required to ensure the success of the EpiFemCare program. GATC-Biotech and Genedata are Europe’s leading providers of DNA sequencing and bioinformatics for biomarker development and have developed serum DNA based prenatal tests. The clinical partners have access to unique cohort and clinical samples collected from >200,000 women well in advance of disease (UK Collaborative Trial of Ovarian Cancer Screening) or before and during treatment (SUCCESS Trial).

IMPACT
As a result of refined and improved patient stratification, EpiFemCare will:
- Reduce the late stage presentation of ovarian & breast cancer by 50%
- Reduce the requirement for 50% of breast cancer patients to have adjuvant therapies
- Reduce female cancer related fatalities as well as treatment-related morbidity by 20%

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

UCL Elizabeth Garrett Anderson Institute for Women’s Health
Address
Gower Street
WC1E 6BT London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 052 712
Administrative Contact
Greta Borg-Carbott (Ms.)

Participants (5)

Eurofins Genomics Europe Sequencing GmbH
Germany
EU contribution
€ 2 136 106
Address
Jakob Stadler Platz 7
78467 Konstanz
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Janet Kenklies (Dr.)
GENEDATA AG
Switzerland
EU contribution
€ 852 245
Address
Margarethenstrasse 38
4053 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Timo Wittenberger (Dr.)
EURAM LIMITED
United Kingdom
EU contribution
€ 354 344
Address
Lucy Tower Street Tower House
LN1 1XW Lincoln
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andrew Banasik (Mr.)
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 249 932
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Brigitte Rack (Dr.)
UNIVERZITA KARLOVA
Czechia
EU contribution
€ 230 048
Address
Ovocny Trh 560/5
116 36 Praha 1
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kristyna Matejkova (Ms.)